Item 5. Other Information
Item 5. Other Information.
During the quarter ended June 30, 2026, one of our directors adopted a “Rule 10b5-1 trading arrangement” as that term is defined in Item 408 of Regulation S-K, as set forth in the table below.
Name and Position
Action
Adoption/ Termination Date
Rule 10b5-1 (1)
Non-Rule 10b5-1 (2)
Total Shares of Common Stock to be Sold
Expiration Date
Christopher Twomey , Director
Adoption
May 19, 2026
X
1,700 (3)
November 15, 2026
(1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
(2) “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.
(3) Mr. Twomey’s Rule 10b5-1 trading plan provides for the potential sale of up to 1,700 shares of common stock issuable upon the exercise of certain stock options set to expire on November 15, 2026.
Except as set forth above, during the quarter ended June 30, 2026, none of our officers (as defined in Rule 16a-1(f) under the Exchange Act) or directors adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” as those terms are defined in Item 408 of Regulation S-K.
76
Item 6. Exhibits.
Incorporated by Reference Provided Herewith
Exhibit Number Exhibit Description Form File No. Date of First Filing Exhibit Number
3.1 Amended and Restated Certificate of Incorporation of the Registrant (as amended and currently in effect).
8-K 001-36189
May 21, 2026 3.1
3.2 Amended and Restated Bylaws of the Registrant (as amended and currently in effect).
8-K 001-36189
December 30, 2025 3.1
10.1 Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended.
8-K 001-36189 May 21, 2026 10.1
31.1 Certification of John F. Sheridan, Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
X
31.2 Certification of Leigh A. Vosseller, Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
X
32.1* Certification of John F. Sheridan, Chief Executive Officer, pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
X
32.2* Certification of Leigh A. Vosseller, Chief Financial Officer, pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
X
101.INS Inline XBRL Instance Document. X
101.SCH Inline XBRL Taxonomy Extension Schema Document. X
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. X
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. X
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. X
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. X
104 Cover Page Interactive Data File (embedded within the Inline XBRL Document contained in Exhibit 101). X
*
This certification is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the registrant specifically incorporates it by reference.
77
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Tandem Diabetes Care, Inc.
Dated: August 6, 2026
By: /s/ John F. Sheridan
John F. Sheridan
President and Chief Executive Officer
(on behalf of the registrant and as the registrant’s
Principal Executive Officer)
Dated: August 6, 2026
By: /s/ Leigh A. Vosseller
Leigh A. Vosseller
Executive Vice President, Chief Financial Officer and Treasurer
(Principal Financial and Accounting Officer)
78
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.